ABSTRACT
El aumento progresivo de las resistencias antibióticas apremia el tener estrategias para disminuir la presión sobre la microbiota. La duración del tratamiento antibiótico empírico es variable, a pesar de las recomendaciones de las guías. Se ha realizado una revisión bibliográfica de la evidencia científica publicada sobre la duración del tratamiento antibiótico empírico en las infecciones intraabdominales quirúrgicas con control de foco efectivo. Se analizan las guías americanas realizadas por Mazuski et al. de 2017 como eje central en las recomendaciones de la duración de tratamiento antibiótico empírico en infecciones intraabdominales con control del foco y se añade una búsqueda bibliográfica de todos los artículos que contuviesen las palabras claves en Pubmed y Google Scholar. Se recopilan 21 artículos referentes en la duración del tratamiento antibiótico empírico en la infección intraabdominal con control del foco. Con las guías americanas y estos artículos se ha elaborado una propuesta de duración del tratamiento antibiótico empírico en pacientes sin factores de riesgo entre 24 y 72 h. Y en los que presentan factores de riesgo se habría de individualizar el mismo con monitorización activa cada 24 h de fiebre, íleo paralítico y leucocitosis, ante una detección precoz de complicaciones o de necesidad de cambios en el espectro antibiótico. Los tratamientos cortos son igual de eficaces que los de duraciones más prolongadas y se asocian a menos tasa de efectos adversos, por tanto, ajustar y revaluar diariamente la duración del tratamiento antibiótico empírico es fundamental para una mejor praxis (AU)
A non-systematic review of the published scientific evidence has been carried out on the duration of empirical antibiotic treatment in surgical intra-abdominal infections with effective focus control. Given the progressive increase in antibiotic resistance, it is urgent to have strategies to reduce the pressure on the microbiota. The American guidelines made by Mazuski et al. of 2017, as the central axis in the recommendations of the duration of empirical antibiotic treatment in intra-abdominal infections with control of the focus and a bibliographic search of all the articles that contained the keywords in Pubmed and Google Scholar is added. 21 articles referring to the duration of empirical antibiotic treatment in intra-abdominal infection with control of the focus are collected. With the American guidelines and these articles, a proposal is prepared for the duration of empirical antibiotic treatment in patients without risk factors between 24 and 72h. And in those who present risk factors, it should be individualized with active monitoring every 24h of fever, paralytic ileus and leukocytosis, before an early detection of complications or the need for changes in antibiotic treatment. Short treatments are just as effective as those of longer durations and are associated with fewer adverse effects, therefore, daily adjusting and reassessing the duration of empirical antibiotic treatment is essential for better practice (AU)
Subject(s)
Humans , Digestive System Diseases/surgery , Digestive System Diseases/classification , Antibiotic Prophylaxis , Anti-Bacterial Agents/administration & dosageABSTRACT
A non-systematic review of the published scientific evidence has been carried out on the duration of empirical antibiotic treatment in surgical intra-abdominal infections (IIA) with effective focus control. Given the progressive increase in antibiotic resistance, it is urgent to have strategies to reduce the pressure on the microbiota. The American guidelines made by Mazuski et al. of 20171, as the central axis in the recommendations of the duration of empirical antibiotic treatment in intra-abdominal infections with control of the focus and a bibliographic search of all the articles that contained the keywords in Pubmed and Google Scholar is added. 21 articles referring to the duration of empirical antibiotic treatment in intra-abdominal infection with control of the focus are collected. With the American guidelines and these articles, a proposal is prepared for the duration of empirical antibiotic treatment in patients without risk factors between 24 and 72 h. And in those who present risk factors, it should be individualized with active monitoring every 24 h of fever, paralytic ileus and leukocytosis (FIL), before an early detection of complications or the need for changes in antibiotic treatment. Short treatments are just as effective as those of longer durations and are associated with fewer adverse effects, therefore, daily adjusting and reassessing the duration of empirical antibiotic treatment is essential for better practice.
Subject(s)
Intraabdominal Infections , Anti-Bacterial Agents/therapeutic use , Humans , Intraabdominal Infections/drug therapy , United StatesABSTRACT
Antecedentes. De la literatura publicada se desprende que las infecciones producidas por hongos dematiáceos afectan con mayor frecuencia a pacientes inmunodeprimidos, y que estas infecciones se manifiestan desde formas subcutáneas hasta formas diseminadas que pueden comprometer la vida del paciente. En muchos casos la infección se relaciona con la inoculación del microorganismo por distintos mecanismos traumáticos, lo que determina que la evolución de la infección muchas veces sea lenta. Caso clínico. Se describen dos casos clínicos de feohifomicosis causados por Phaeoacremonium parasiticum, con un paciente oncológico con lesiones subcutáneas que afectaban a la mano y antebrazo izquierdos, y otro paciente que presentaba abscesos subcutáneos en la pierna izquierda. Conclusiones. Estos casos confirman la presencia de este hongo en España y demuestran la complejidad en el tratamiento. Fue necesario el uso combinado de anfotericina B (complejo lipídico) y de posaconazol, junto con varias resecciones quirúrgicas, para poder conseguir superar la infección que presentaba uno de los pacientes (AU)
Background. From the available literature, it is demonstrated that dematiaceous fungal infections mostly affect immunosuppressed patients. These infections can occur in different forms, from subcutaneous infection to disseminated forms that may compromise the life of the patient. In many cases the infection is related to the inoculation of the microorganism by diverse traumatic mechanisms, which determines the course of the infection to be slower in some cases. Case report. We describe two cases of phaeohyphomycosis caused by Phaeoacremonium parasiticum: A cancer patient with subcutaneous lesions affecting the left hand and forearm, and a patient who presented with subcutaneous abscesses in the left leg. Conclusions. These cases confirm the presence of this type of fungus in Spain. In the second case a combination of amphotericin B lipid complex and posaconazole, together with several surgical resections, were necessary in order to overcome the infection (AU)
Subject(s)
Aged , Humans , Male , Phaeohyphomycosis/diagnosis , Kidney Transplantation , Dermatomycoses/complications , Antifungal Agents/therapeutic use , Abscess/microbiology , Subcutaneous Tissue/microbiologyABSTRACT
BACKGROUND: From the available literature, it is demonstrated that dematiaceous fungal infections mostly affect immunosuppressed patients. These infections can occur in different forms, from subcutaneous infection to disseminated forms that may compromise the life of the patient. In many cases the infection is related to the inoculation of the microorganism by diverse traumatic mechanisms, which determines the course of the infection to be slower in some cases. CASE REPORT: We describe two cases of phaeohyphomycosis caused by Phaeoacremonium parasiticum: A cancer patient with subcutaneous lesions affecting the left hand and forearm, and a patient who presented with subcutaneous abscesses in the left leg. CONCLUSIONS: These cases confirm the presence of this type of fungus in Spain. In the second case a combination of amphotericin B lipid complex and posaconazole, together with several surgical resections, were necessary in order to overcome the infection.
Subject(s)
Abscess/microbiology , Ascomycota/isolation & purification , Dermatomycoses/microbiology , Opportunistic Infections/microbiology , Aged , Antifungal Agents/therapeutic use , Cellulitis/etiology , Diabetes Mellitus, Type 2/complications , Fatal Outcome , Hand Dermatoses/microbiology , Humans , Immunocompromised Host , Kidney Transplantation , Male , Neoplasms, Multiple Primary/complicationsABSTRACT
No disponible
Subject(s)
Humans , Female , Young Adult , Streptococcus equi/isolation & purification , Streptococcal Infections/microbiology , Meningitis, Bacterial/microbiology , Zoonoses/microbiology , Risk Factors , Animals, DomesticABSTRACT
No disponible
No disponible
